Healio

Gene therapy increases factor VIII activity, reduces bleeding in severe hemophilia A

Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
European Medical Journal

EAHAD 2026: Factor VIII Activity Measurement Improves with Calibrators

Data presented at EAHAD 2026 show product-specific calibration improves factor VIII activity measurement accuracy.
ascopubs.org

Elevated factor VIII activity is common in patients with newly diagnosed high-grade gliomas

Patupilone for the treatment of recurrent/progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): An open-label phase II study No significant financial relationships to ...
clinicaladvisor.com

Recombinant factor VIII for hemophilia A

Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...
Nature

Stimulation of Factor VIII (Antihæmophilic) Activity by Transfused Serum

PATIENTS with factor VIII deficiency and prolonged skin bleeding time (von Willebrand's syndrome) who receive fresh blood or plasma from normal donors or from patients with hæmophilia A with very low ...
The New England Journal of Medicine

The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A

Factor VIII inhibitors are IgG alloantibodies that arise during replacement therapy in 25 to 50 percent of patients with severe hemophilia A. The hydrolysis of factor VIII by anti–factor VIII ...
Yahoo Finance

Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

Paris and Stockholm – February 23, 2023 – The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously ...
Nature

Separation of Factor VIII (Antihaemophilic Factor) Activity from Fibrinogen by Means of a Snake Venom

THE separation of Factor VIII activity from fibrinogen is of considerable importance. From the therapeutic point of view it would seem desirable when treating haemophiliacs to use a protein fraction ...
The New England Journal of Medicine

Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A

An open-label, phase 1 trial was conducted in six patients with severe hemophilia A. Dermal fibroblasts obtained from each patient by skin biopsy were grown in culture and transfected with a plasmid ...
Healio

Investigational gene therapy leads to sustained factor VIII expression in hemophilia A

Please provide your email address to receive an email when new articles are posted on . The novel gene therapy SPK-8011 induced sustained factor VIII expression in patients with hemophilia A, ...
Business Wire

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following ...

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase ...
Medscape

EMA Approves Factor VIII Deficiency Clotting Drug

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...